Japanese Gastroenterologists Back Earlier UC Treatment, but Step-Up Approach Dominates — Spherix Global Insights

Event summary

73% of Japanese gastroenterologists believe long-term risks of uncontrolled UC outweigh advanced therapy risks, but step-up treatment remains dominant.
Only 52% of physicians support top-down treatment for moderate-to-severe UC patients, despite 48% of patients not receiving advanced therapy.
TNF inhibitors hold the largest market share, but JAK inhibitors and IL-23 inhibitors are gaining favor.
AbbVie’s Rinvoq leads among newer advanced agents, while J&J’s Tremfya captures disproportionate new prescriptions.
40% of physicians cite institutional or administrative constraints as barriers to earlier advanced therapy initiation.

The big picture

Japan’s UC treatment landscape is becoming increasingly competitive as biologics, JAK inhibitors, and S1P modulators expand physician choice. However, the gap between treatment philosophy and prescribing behavior highlights institutional and clinical barriers to earlier advanced therapy adoption. Manufacturers must demonstrate compelling efficacy, safety, and Japan-specific evidence to shift established treatment patterns.

What we're watching

Guideline Influence: Whether JSGE guideline inclusion will drive adoption of newer therapies despite clinical evidence.
Pipeline Differentiation: How late-stage pipeline agents address unmet needs in women of childbearing age and treatment-resistant patients.
Prescribing Evolution: The pace at which JAK inhibitors and IL-23 inhibitors gain market share over TNF inhibitors.